Grufity logoGrufity logo
StocksFundsSearch Filings

Ocular Therapeutix Inc Stock Research

OCUL

6.92USD+0.50(+7.79%)Market Closed

Market Summary

USD6.92+0.50
Market Closed
7.79%

OCUL Alerts

OCUL Stock Price

OCUL RSI Chart

OCUL Valuation

Market Cap

536.4M

Price/Earnings (Trailing)

-6.04

Price/Sales (Trailing)

10.38

Price/Free Cashflow

-7.91

OCUL Price/Sales (Trailing)

OCUL Profitability

Return on Equity

-200.79%

Return on Assets

-47.58%

Free Cashflow Yield

-12.64%

OCUL Fundamentals

OCUL Revenue

Revenue (TTM)

51.7M

Revenue Y/Y

1.42%

Revenue Q/Q

-4.98%

OCUL Earnings

Earnings (TTM)

-88.8M

Earnings Y/Y

-141.73%

Earnings Q/Q

-95.07%

Price Action

52 Week Range

2.577.32
(Low)(High)

Last 7 days

10.2%

Last 30 days

11.8%

Last 90 days

17.1%

Trailing 12 Months

117.6%

OCUL Financial Health

Current Ratio

4.13

OCUL Investor Care

Shares Dilution (1Y)

0.99%

Diluted EPS (TTM)

-1.19

Peers (Alternatives to Ocular Therapeutix)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
409.0B
96.3B
-3.62% -9.57%
32.14
4.25
1.46% -35.83%
398.5B
27.7B
2.58% 47.15%
70.08
14.39
-5.56% -7.22%
272.8B
57.9B
-4.82% 28.79%
17.88
4.63
7.21% -8.11%
230.9B
93.0B
-0.23% -25.99%
7.36
2.3
0.56% 16.36%
150.1B
45.8B
-1.47% -11.26%
23.72
3.25
-2.37% 16.96%
MID-CAP
5.0B
4.6B
-12.00% -16.92%
-35.25
1.11
8.46% -29.07%
3.5B
1.5M
-8.84% 225.36%
-11.32
1.6K
-86.94% -16.59%
SMALL-CAP
1.8B
668.5M
-9.91% 19.28%
34.95
2.72
11.17% -29.04%
1.6B
596.3M
-7.75% -62.41%
-0.89
2.66
-3.41% -3791.67%
866.9M
271.5M
14.22% -13.24%
3.94
3.19
-31.50% -40.28%
666.4M
112.3M
-6.91% -41.08%
-4.29
5.94
7.69% 41.96%
590.7M
30.8M
-2.33% -39.30%
-6.14
19.16
378.90% -19.01%
536.4M
51.7M
11.79% 117.61%
-6.04
10.38
4.69% -299.77%
401.1M
478.9M
-31.81% -82.48%
-0.13
0.84
-31.50% -634.70%
94.1M
2.2B
-43.99% -88.43%
-0.03
0.04
-25.47% -292.77%

Financials for Ocular Therapeutix

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue0.4%51,68051,49449,72649,91449,366
  S&GA Expenses4.4%41,69339,92238,52537,91536,166
  R&D Expenses3.1%55,10953,46252,49751,49752,256
Interest Expenses1.2%7,1087,0226,8566,7176,676
Net Income-25.0%-88,814-71,038-59,346-32,501-22,216
Net Income Margin-15.6%-1.38*-1.19*-0.65*-0.45*-
Free Cahsflow-5.5%-63,318-59,994-59,289-68,103-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-13.9%129149159173188
  Current Assets-17.3%107130146160175
    Cash Equivalents-21.0%81.00102121135145
  Inventory14.8%2.002.002.002.001.00
  Net PPE22.0%12.0010.007.007.007.00
Liabilities4.3%119114112107108
  Current Liabilities-5.4%30.0031.0029.0026.0024.00
Shareholder's Equity-72.6%10.0035.0046.0066.0080.00
  Retained Earnings-4.9%-647-616-601-577-558
  Additional Paid-In Capital0.7%657652648643638
Shares Outstanding0.4%78.0077.0077.0077.0077.00
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-2.3%-60,976-59,603-57,798-57,611-66,791
  Share Based Compensation2.1%17,32716,96416,57116,08916,100
Cashflow From Investing-83.5%-6,818-3,715-2,196-1,678-1,312
Cashflow From Financing-3.5%1,4031,4541,6631,9684,142

Risks for OCUL

What is the probability of a big loss on OCUL?

98.8%


Probability that Ocular Therapeutix stock will be more than 20% underwater in next one year

97.3%


Probability that Ocular Therapeutix stock will be more than 30% underwater in next one year.

72.3%


Probability that Ocular Therapeutix stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OCUL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.

Drawdowns

Returns for OCUL

Cumulative Returns on OCUL

-7.4%


7-Year Cumulative Returns

0.3%


5-Year Cumulative Returns

-0.7%


3-Year Cumulative Returns

What are the long-term rolling returns for OCUL?

FIve years rolling returns for Ocular Therapeutix.

Annualized Returns

Which funds bought or sold OCUL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-11.52
30,172
75,930
-%
2023-05-22
AMERIPRISE FINANCIAL INC
added
16.51
101,663
186,663
-%
2023-05-18
JPMORGAN CHASE & CO
added
38.69
207,000
337,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-41.11
16,000
166,000
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
615
1,318
-%
2023-05-16
ATLAS CAPITAL ADVISORS LLC
unchanged
-
12,300
26,350
-%
2023-05-16
JANE STREET GROUP, LLC
added
323
539,212
616,832
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
84.87
917,179
1,288,930
-%
2023-05-15
Cubist Systematic Strategies, LLC
new
-
226,552
226,552
-%
2023-05-15
Quantamental Technologies LLC
new
-
70,254
70,254
0.04%

1–10 of 42

Latest Funds Activity

Are funds buying OCUL calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own OCUL
No. of Funds

Ocular Therapeutix News

Yahoo Eurosport UK
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is definitely on the radar of institutional investors who own 45% of the company.
Yahoo Eurosport UK,
21 hours ago
Greenwich Time
InvestorsObserver

Schedule 13G FIlings of Ocular Therapeutix

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
opaleye management inc.
7.89%
6,075,000
SC 13G/A
Feb 09, 2023
vanguard group inc
5.16%
3,976,853
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
4,952,737
SC 13G/A
Feb 03, 2022
blackrock inc.
6.7%
5,122,835
SC 13G/A
Feb 01, 2022
opaleye management inc.
7.80%
5,974,800
SC 13G/A
Feb 12, 2021
opaleye management inc.
8.65%
9
SC 13G/A
Feb 02, 2021
blackrock inc.
7.3%
5,512,264
SC 13G
Jun 09, 2020
blackrock inc.
4.8%
3,006,167
SC 13G/A
May 21, 2020
summer road llc
17.0%
11,387,656
SC 13D/A
Mar 25, 2020
summer road llc
18.9%
11,024,020
SC 13D/A

OCUL Fair Value

Show Fair-Value

Recent SEC filings of Ocular Therapeutix

View All Filings
Date Filed Form Type Document
May 08, 2023
8-K
Current Report
May 08, 2023
10-Q
Quarterly Report
May 01, 2023
DEFA14A
DEFA14A
May 01, 2023
DEF 14A
DEF 14A
May 01, 2023
ARS
ARS
Apr 06, 2023
8-K
Current Report
Mar 06, 2023
S-8
Employee Benefits Plan
Mar 06, 2023
8-K
Current Report
Mar 06, 2023
10-K
Annual Report

Latest Insider Trading transactions for OCUL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-06
Mattessich Antony C.
sold
-83,396
4.24
-19,669
president and ceo
2023-02-06
White Christopher G
sold
-24,715
4.24
-5,829
chief business officer
2023-02-06
Ozden Rabia Gurses
sold
-27,203
4.24
-6,416
chief medical officer
2023-02-06
Notman Donald
sold
-27,458
4.24
-6,476
chief financial officer
2023-02-06
Strassburger Philip C.
sold
-26,207
4.24
-6,181
general counsel
2023-01-30
Notman Donald
acquired
-
-
55,556
chief financial officer
2023-01-30
Ozden Rabia Gurses
acquired
-
-
55,556
chief medical officer
2023-01-30
Strassburger Philip C.
acquired
-
-
55,556
general counsel
2023-01-30
Mattessich Antony C.
acquired
-
-
176,300
president and ceo
2023-01-30
White Christopher G
acquired
-
-
44,444
chief business officer

1–10 of 50

Antony Mattessich
230
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:  
Total revenue, net$ 13,374$ 13,187
Costs and operating expenses:  
Cost, Product and Service [Extensible List]ProductProduct
Cost of product revenue$ 1,214$ 1,300
Research and development14,74713,100
Selling and marketing10,8359,063
General and administrative9,1277,557
Total costs and operating expenses35,92331,020
Loss from operations(22,549)(17,833)
Other income (expense):  
Interest income56318
Interest expense(1,768)(1,683)
Change in fair value of derivative liability(6,563)6,958
Other expense, net(1)(2)
Total other (expense) income, net(7,769)5,291
Net loss$ (30,318)$ (12,542)
Net loss per share, basic$ (0.39)$ (0.16)
Weighted average common shares outstanding, basic77,386,28776,745,663
Net loss per share, diluted$ (0.39)$ (0.22)
Weighted average common shares outstanding, diluted77,386,28782,514,895
Product  
Revenue:  
Total revenue, net$ 13,214$ 12,498
Collaboration revenue  
Revenue:  
Total revenue, net$ 160$ 689

OCUL Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 79,026$ 102,300
Accounts receivable, net21,12421,325
Inventory2,2661,974
Prepaid expenses and other current assets4,7464,028
Total current assets107,162129,627
Property and equipment, net12,0229,856
Restricted cash1,7641,764
Operating lease assets7,6258,042
Total assets128,573149,289
Current liabilities:  
Accounts payable5,4415,123
Accrued expenses and other current liabilities21,99324,097
Deferred revenue463576
Operating lease liabilities1,8181,599
Total current liabilities29,71531,395
Other liabilities:  
Operating lease liabilities, net of current portion8,1148,678
Derivative liability12,9146,351
Deferred revenue, net of current portion13,34013,387
Notes payable, net of discount25,32125,257
Other non-current liabilities10093
2026 convertible notes, net29,35828,749
Total liabilities118,862113,910
Commitments and contingencies (Note 14)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,516,638 and 77,201,819 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively88
Additional paid-in capital656,863652,213
Accumulated deficit(647,160)(616,842)
Total stockholders' equity9,71135,379
Total liabilities and stockholders' equity$ 128,573$ 149,289